Preparing for success with comparative effectiveness research
- PMID: 23814162
- PMCID: PMC4063389
- DOI: 10.1634/theoncologist.2013-0213
Preparing for success with comparative effectiveness research
Abstract
This commentary reviews the work on Comparative Effectiveness Research (CER) published in this issue by Gary Lyman and Scott Ramsey et al., concluding that CER will play a key role in optimizing outcomes for cancer patients in the future.
Conflict of interest statement
Comment on
-
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.Oncologist. 2013 Jun;18(6):760-7. doi: 10.1634/theoncologist.2012-0386. Epub 2013 May 6. Oncologist. 2013. PMID: 23650020 Free PMC article.
-
Comparative effectiveness research in oncology.Oncologist. 2013 Jun;18(6):752-9. doi: 10.1634/theoncologist.2012-0445. Epub 2013 May 22. Oncologist. 2013. PMID: 23697601 Free PMC article.
References
-
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. - PubMed
-
- Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. [Accessed May 28,2013]. Available at: http://www.fda.gov/Drugs/lnformationOnDrugs/ApprovedDrugs/ucm279174.htm.
-
- Hoch JS, Hodgson DC, Earle CC. Role of comparative effectiveness research in cancer funding decisions in Ontario, Canada. J Clin Oncol. 2012;30:4262–6. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources